SEOUL, South Korea (BUSINESS WIRE) A clinical-staged proprietary platform technology biotech company Genexine (KQ 095700, CEO Neil Warma) and its Asian regional partner, KG Bio unveiled the interim results of phase 3 clinical trial of GX-E4 (Efepoetin alfa), a candidate for CKD (Chronic Kidney Disease) induced ane.
News - Prof Elmi Muller takes the helm at FMHS sun.ac.za - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sun.ac.za Daily Mail and Mail on Sunday newspapers.